Topical Treatment for TMJ Arthralgia

Part of paid clinical trials in San Francisco, California.

Sponsor
University of the Pacific
Study ID
NCT05816226
Phase
PHASE3
Status
Recruiting
Apply to this trial

Conditions

  • TMJ Pain

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Hydrocortisone 2.5% — DRUG
    Applied four times daily to TMJ with arthralgia
  • Diclofenac 1% topical — DRUG
    Applied four times daily to TMJ with arthralgia

Study Details

The goal of this clinical trial is to evaluate the efficacy of topical 2.5% hydrocortisone in TMJ arthralgia. The main questions it aims to answer are: * How does pain reduction compare? * How does improvement in jaw function limitation compare? * How do side effects compare? Participants will * On day 1 be examined and report their pain level and jaw function limitation * On days 1-21, apply their cream four times a day * On day 21, report their pain level, jaw function limitation, compliance with instructions, and side effects. Researchers will compare topical 2.5% hydrocortisone and topical 1% diclofenac to see if efficacy and side effects differ.

Key Dates

Start date
Jun 1, 2023
Status verified
Dec 2024
Primary completion
Jan 31, 2026
Completion
Apr 30, 2026

Study Design

Enrollment
90 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Hydrocortisone topical
    2.5% hydrocortisone cream
  • Active Comparator: Diclofenac topical
    1% diclofenac cream

Primary Outcome Measure

Change in pain intensity [ Time Frame: Pain measured on days 1 and 21 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Arthur A. Dugoni School of Dentistry, University of the PacificSan FranciscoCalifornia94103
Andrew Young, DDS, MSD
[email protected]
4159296611

Find similar trials in San Francisco, CA

By research site
Arthur A. Dugoni School of Dentistry, University of the Pacific· San Francisco, CA

Related Studies